- Inappropriate testing incident at Kyushu Factory
- Drug supply shortage in Japan
- Rising raw material and utility costs
- Lower NHI drug prices due to annual drug price revisions
- Fierce competition in the US generic drug market
- High employee turnover rate, particularly at manufacturing workplaces
- Climate change risks (policy and legal risks, population, economic, and geopolitical risks, flood risks)
Sawai Group Holdings Co., Ltd.
Greenhouse gas emissions & sustainability report data
In its 2023-04 to 2024-03 reporting, Sawai Group Holdings Co., Ltd. disclosed greenhouse gas emissions of 69.8K t-CO2. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
69.8K t-CO2
2023-04 to 2024-03
Water Usage
2.3K thousand m3
2023-04 to 2024-03
Waste
2.1K tons
2023-04 to 2024-03
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023-04 to 2024-03 | 69.8K t-CO2 |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Recycled 11.1 t of PTP sheet waste material, reducing CO2 emissions to 28.13 t/CO2t
- Reduced electricity consumption by approximately 330,000 kWh annually at Sanda Nishi factory
- Completed third-party verification of fiscal 2022 environmental data
🎯 Climate & Sustainability Targets
🔜 Short-term
- Complete introduction of Quality Event Management System (QMS) no later than fiscal 2024
- Company production capacity: 22.0 billion tablets or more by end of fiscal 2026
- Ratio of women in managerial positions: 15% or more by end of March 2027
- Waste plastic recycling rate of 65% or more by FY2030
- Compared to FY2013+α level, 46% reduction of total emissions volume by FY2030
📅 Medium-term
- Company production capacity: 22.0 billion tablets or more by end of fiscal 2026
- Launch 44 or more new products over three years
- Ratio of women in managerial positions: 15% or more by end of March 2027
- ROE of 10% or more, ROIC of 8% or more, net D/E ratio of 0.4 or less, capital ratio of 50% or more, and DOE of 3.0% or more by end of fiscal 2026
- Generics business revenue of ¥219.0 billion by end of fiscal 2026
🔭 Long-term
- Generics business revenue of ¥300.0 billion by fiscal 2030
- Generics market share of 25% or more by fiscal 2030
- In-house production capacity of 25.0 billion tablets or more by fiscal 2030
- ROE of 13% or more and ROIC of 10% or more by fiscal 2030
🌱 ESG Focus Areas
Product quality and safetyMaintaining a stable supplyDevelopment of high value-added generic drugsSecuring production, quality, and R&D talentPromoting inclusion, diversity and equity (ID&E)Improving employee engagementWorking on human rights due diligenceEnhancing risk management and complianceExpanding business to a wider range of healthcare domainsEnhancing supply chain managementEnsuring the reliability of non-financial informationStrengthening information securityPromotion of recycling and the reduction of energy use and wasteWater use reductionConservation of biodiversityResponding to climate change